

## Focus on Diabetes Management: Postprandial Glucose

Sylvia Wong, Pharm.D.

### References

1. American Diabetes Association. Total prevalence of diabetes & pre-diabetes [webpage]. <http://www.diabetes.org/diabetes-statistics/prevalence.jsp>. Accessed 11/7/2006.
2. American Diabetes Association. Standards of medical care in diabetes—2006 [position statement]. *Diabetes Care* 2006;29 Suppl 1:S4-42.
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 1993;329(14):977-86.
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 1998;352(9131):837-53.
5. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ* 2000;321(7258):405-12.
6. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. *N Engl J Med* 2005 (Dec 22);353(25):2643-53.
7. Charpentier G, Riveline JP, Dardari D, Varroud-Vial M. Should postprandial hyperglycaemia in prediabetic and type 2 diabetic patients be treated? *Drugs* 2006;66(3):273-86.
8. de Vegt F, Dekker JM, Ruhe HG, et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. *Diabetologia* 1999;42(8):926-31.
9. Shaw JE, Hodge AM, de Courten M, Chitson P, Zimmet PZ. Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. *Diabetologia* 1999;42(9):1050-4.
10. Meigs JB, Nathan DM, D'Agostino RB, Sr., Wilson PW. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. *Diabetes Care* 2002;25(10):1845-50.
11. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. *Arch Intern Med* 2001;161(3):397-405.
12. Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. *Diabetologia* 1996;39(12):1577-83.
13. Esposito K, Giugliano D, Nappo F, et al. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. *Circulation* 2004 (Jul 13);110(2):214-9.
14. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. *Int J Clin Pract*. 2006 Nov;60(11):1454-70.
15. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. *Diabetologia* 2006;49(11):2564-71.

---

A University of Washington Drug Information Center publication  
Distributed monthly by authority of the Pharmacy and Therapeutics Committee  
Editor: Nelda A. Murri, Pharm.D. (206) 598-6612 – Asst. Editor: Elizabeth Rudy, D.V.M., R.Ph.  
Department of Pharmacy Services / School of Pharmacy

---

Copyright © 2006 by the University of Washington  
Also published at <http://uw.pnrx.org/therapyTopics.asp>  
No material may be reproduced in whole or in part without written permission from the editor.